Experts disagree on whether prostate cancer with a Gleason score of 6 (GS6) should be re-labeled as non-cancerous. Writing in a commentary in the Journal of Clinical Oncology, Scott Eggener, MD, and ...
Bottom Line: Establishing the way in which a genetic alteration called a TMPRSS2-ERG gene fusion forms in a prostate cancer, rather than the presence of the gene fusion itself, could help identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results